12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BG-12: Phase III data

Top-line data from the double-blind, international Phase III DEFINE trial in >1,200 patients showed that twice- and thrice-daily 240 mg oral BG-12 met the primary endpoint of significantly reducing the proportion of patients who relapsed at 2 years vs. placebo (p<0.0001). Both doses of BG-12 also met all secondary endpoints vs. placebo at 2 years, including significantly...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >